European Heart Journal-Cardiovascular Pharmacotherapy

Journal website Submission website

Note: The following journal information is for reference only. Please check the journal website for updated information prior to submission.

Journal Title

EUR HEART J-CARD PHA

ISSN / eISSN

2055-6837 / 2055-6845

Aims and Scope

The European Heart Journal - Cardiovascular Pharmacotherapy is a new, international journal published on behalf of the European Society of Cardiology and the Working Group on Cardiovascular Pharmacotherapy. The Journal is freely available until December 2016.

This Journal aims to publish the highest quality research, interpreting and integrating new scientific developments within the field of cardiovascular pharmacotherapy. The overarching goal of the Journal is to improve the care of patients with cardiovascular disease with a specific focus on cardiovascular pharmacotherapy.

Subject Area

PHARMACOLOGY & PHARMACY

CARDIAC & CARDIOVASCULAR SYSTEMS

CiteScore

8.90

View Trend

CiteScore Ranking

Category	Quartile	Rank
Medicine - Pharmacology (medical)	Q1	#28/260
Medicine - Cardiology and Cardiovascular Medicine	Q1	#43/354

Web of Science Core Collection

Science Citation Index Expanded (SCIE)	Social Sciences Citation Index (SSCI)
Indexed	-

Category (Journal Citation Reports 2023)	Quartile
CARDIAC & CARDIOVASCULAR SYSTEMS - SCIE	Q1
PHARMACOLOGY & PHARMACY - SCIE	Q1

Country/Area of Publication

United Kingdom

Publisher

Oxford University Press

Annual Article Volume

Open Access

Contact

GREAT CLARENDON ST, OXFORD, ENGLAND, OX2 6DP

Popular journals in the same field
Recent articles

Factor XIa inhibitors: collecting the clinical evidence: (2023) Basil S Lewis, Koji Hasegawa

Non-steroidal anti-inflammatory drugs and risk of pulmonary embolism in patients with inflammatory joint disease - results from the nationwide Norwegian Cardio-rheuma registry: (2023) Eirik Ikdahl, Silvia Rollefstad, Amirhossein Kazemi, Sella A Provan, Trine-Lise Larsen, Anne Grete Semb

Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation at Low Risk of Stroke in Japan: A Retrospective Cohort Study: (2023) Masato Uchida, Taisuke Jo, Akira Okada, Hiroki Matsui, Hideo Yasunaga

Antiplatelet treatment after PCI: (2023) Stefan Agewall

Anticoagulation in cancer-associated thrombosis: how long should the therapy be?: (2023) Wei Xiong, Stefan Agewall, Yugo Yamashita

Novel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease: (2023) Wayne C Zheng, William Chan, Anthony Dart, James A Shaw

A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies: (2023) Joanna Osmanska, Katriona Brooksbank, Kieran F Docherty, Stacy Robertson, Kirsty Wetherall, Alex McConnachie, Jerry Hu, Roy S Gardner, Andrew L Clark,...

Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study: (2023) Maxim Grymonprez, Laura Carnoy, Andreas Capiau, Koen Boussery, Els Mehuys, Tine L De Backer, Stephane Steurbaut, Lies Lahousse

GLP-1 receptor agonists: new game changing drugs in patients with heart failure with preserved ejection fraction and obesity: (2023) Eri Toda Kato, Basil S Lewis, Koh Ono

Predictive value of the thrombotic risk criteria proposed in the 2023 ESC guidelines for the management of ACS: insights from a large PCI registry: (2023) Alessandro Spirito, Davide Cao, Samantha Sartori, Ashutosh Sharma, Kenneth F Smith, Birgit Vogel, Karim Kamaleldin, Anoop N Koshy, Yihan Feng, David P...

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started